BioGroup - comment

BioGroup shareholders have informally appointed Centerview Partners to explore options for an exit. This appears to be at the preliminary stage, with initial valuations at €5bn or 10-11x EBITDA. However, with expected downward pressure on tariffs due to the French budgetary constraints, a sale of lofty multiples is not a forgone conclusion. 

The shareholders include the Eimer family at c.36%, De Raedt-Verheyden family (the former owners of the Belgian business), 10%, plus financial investors, including Caisse de dépôt et placement du Québec, ICG and EMZ Partners.